3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with HIV Coinfection in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Angerer, A; Antke, C; Arendt, G; Carey, P; Husstedt, IW; Koutsilieri, E; Maschke, M; Meisner, F; Müller, HW; Neuen-Jacob, E; Nolting, T; Obermann, M; Riederer, P; Scheller, C; Sopper, S; Ter Meulen, V | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and HIV Coinfection
Article | Year |
---|---|
Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Benzamides; Case-Control Studies; CD4 Antigens; Chemokine CCL2; Dopamine; Galactosephosphates; HIV; HIV Infections; Homovanillic Acid; Humans; Male; Middle Aged; Pyrrolidines; Synaptic Transmission; Tomography, Emission-Computed, Single-Photon; Tropanes; Viral Load | 2010 |